Shield Therapeutics (GB:STX) has released an update.
Shield Therapeutics reports a robust 69% increase in Q2 2024 ACCRUFeR® revenues, reaching $6.9 million, propelled by a 26% rise in prescriptions and a 23% hike in the drug’s average net selling price. The company’s strong market performance is supported by significant year-over-year growth and a solid financial position, with $8.1 million in cash and an additional $5.7 million from a recent milestone in China. Interim CEO Anders Lundstrom credits the growth to increased physician adoption and market potential for ACCRUFeR®, the company’s innovative iron deficiency treatment.
For further insights into GB:STX stock, check out TipRanks’ Stock Analysis page.
